Nomenclature: 5-HT1B receptor

Family: 5-Hydroxytryptamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

Contents

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 390 6q13 HTR1B 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 15,21,43,53,80
Mouse 7 386 9 E1 Htr1b 5-hydroxytryptamine (serotonin) receptor 1B 36
Rat 7 386 8q31 Htr1b 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 1,74
Previous and Unofficial Names
Names References
5-HT1Dβ 53,80
S12
5-HT1B
HTR1D2
5-HT1DB
5-hydroxytryptamine (serotonin) receptor 1B
serotonin (5-hydroxytryptamine (5HT)) receptor, type 1B
5-HT-1B
5-HT1B serotonin receptor
5-hydroxytryptamine receptor 1B
Serotonin (5-hydroxytryptamine (5HT)) receptor type 1B
serotonin receptor 1B
5-HT1B receptor
5-HT<1B> receptor
5HT1B receptor
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine
PDB Id:  4IAQ
Ligand:  dihydroergotamine
Resolution:  2.8Å
Species:  Human
References:  75
Image of receptor 3D structure from RCSB PDB
Description:  Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine
PDB Id:  4IAR
Ligand:  ergotamine
Resolution:  2.7Å
Species:  Human
References:  75
Natural/Endogenous Ligand(s)
5-HT
Comments: Endogenous ligand tryptamine is a weak agonist
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]GTI Rn Agonist 8.9 pKd 6
pKd 8.9 (Kd 1.3x10-9 M) [6]
[3H]8-OH-DPAT Hs Full agonist 8.9 pKd 48
pKd 8.9 [48]
[3H]alniditan Hs Full agonist 8.6 – 9.0 pKd 28
pKd 8.6 – 9.0 (Kd 1x10-9 – 2.51x10-9 M) [28]
[3H]eletriptan Hs Partial agonist 8.5 pKd 46
pKd 8.5 (Kd 3x10-9 M) [46]
[3H]sumatriptan Hs Partial agonist 8.0 pKd 46
pKd 8.0 (Kd 1.1x10-8 M) [46]
5-HT Hs Full agonist 7.5 – 8.4 pKd 51,80
pKd 7.5 – 8.4 [51,80]
donitriptan Rn Partial agonist 9.7 pKi 22
pKi 9.7 [22]
oxymetazoline Hs Full agonist 9.5 pKi 26
pKi 9.5 [26]
donitriptan Hs Full agonist 9.4 pKi 22
pKi 9.4 [22]
GR-127935 Hs Partial agonist 9.0 – 9.8 pKi 13,24,57,65,79
pKi 9.0 – 9.8 [13,24,57,65,79]
L-694,247 Hs Full agonist 9.2 pKi 14
pKi 9.2 [14]
SB 216641 Hs Partial agonist 9.0 pKi 57
pKi 9.0 [57]
alniditan Hs Full agonist 8.8 – 9.0 pKi 29
pKi 8.8 – 9.0 [29]
7-methoxy-1-naphthylpiperazine Hs Full agonist 8.7 pKi 24
pKi 8.7 [24]
CP94253 Hs Full agonist 8.7 pKi 25
pKi 8.7 (Ki 2x10-9 M) [25]
dihydroergotamine Hs Full agonist 8.0 – 9.2 pKi 29,51
pKi 8.0 – 9.2 [29,51]
CGS-12066 Hs Full agonist 8.1 – 8.7 pKi 14,80
pKi 8.1 – 8.7 [14,80]
ziprasidone Hs Full agonist 8.3 pKi 64
pKi 8.3 [64]
5-CT Hs Full agonist 7.7 – 8.8 pKi 51,80
pKi 7.7 – 8.8 [51,80]
5-(nonyloxy)-tryptamine Hs Full agonist 8.2 pKi 14
pKi 8.2 [14]
lysergol Hs Full agonist 7.5 – 8.9 pKi 51,80
pKi 7.5 – 8.9 [51,80]
5-HT Hs Full agonist 7.4 – 9.0 pKi 9,47-48,65,79-80
pKi 7.4 – 9.0 [9,47-48,65,79-80]
asenapine Hs Full agonist 8.1 pKi 64
pKi 8.1 [64]
naratriptan Hs Partial agonist 8.1 pKi 46
pKi 8.1 [46]
5-CT Mm Full agonist 8.1 pKi 36
pKi 8.1 [36]
RU 24969 Hs Full agonist 8.1 pKi 36
pKi 8.1 [36]
5-HT Mm Full agonist 8.1 pKi 36
pKi 8.1 [36]
eletriptan Hs Full agonist 8.0 pKi 46
pKi 8.0 [46]
BMS 181,101 Hs Partial agonist 7.6 – 8.1 pKi 47
pKi 7.6 – 8.1 [47]
1-naphthylpiperazine Hs Full agonist 7.7 – 7.9 pKi 24,51,80
pKi 7.7 – 7.9 [24,51,80]
lisuride Hs Partial agonist 7.7 pKi 40
pKi 7.7 [40]
zolmitriptan Hs Partial agonist 7.7 pKi 46
pKi 7.7 [46]
5-MeOT Hs Full agonist 7.3 – 7.5 pKi 51,80
pKi 7.3 – 7.5 [51,80]
dipropyl-5-CT Hs Full agonist 7.4 pKi 80
pKi 7.4 [80]
sumatriptan Hs Partial agonist 6.5 – 8.1 pKi 14,29,41,46-47,51,80
pKi 6.5 – 8.1 [14,29,41,46-47,51,80]
xanomeline Hs Full agonist 7.3 pKi 77
pKi 7.3 [77]
rizatriptan Hs Partial agonist 6.9 pKi 46
pKi 6.9 [46]
L-775,606 Hs Partial agonist 6.3 – 6.9 pKi 47
pKi 6.3 – 6.9 [47]
pergolide Hs Full agonist 6.6 pKi 40
pKi 6.6 [40]
terguride Hs Partial agonist 6.6 pKi 40
pKi 6.6 [40]
TFMPP Hs Full agonist 6.2 – 6.9 pKi 51,80
pKi 6.2 – 6.9 [51,80]
bromocriptine Hs Partial agonist 6.5 pKi 40
pKi 6.5 [40]
olanzapine Hs Full agonist 6.3 pKi 64
pKi 6.3 [64]
tryptamine Hs Full agonist 6.3 pKi 80
pKi 6.3 [80]
LY344864 Hs Full agonist 6.3 pKi 54
pKi 6.3 [54]
cabergoline Hs Full agonist 6.3 pKi 40
pKi 6.3 [40]
clozapine Hs Full agonist 6.2 pKi 64
pKi 6.2 [64]
2-methyl-5-HT Hs Full agonist 6.1 pKi 80
pKi 6.1 [80]
aripiprazole Hs Full agonist 6.1 pKi 66
pKi 6.1 [66]
BRL-15572 Hs Partial agonist 6.1 pKi 57
pKi 6.1 [57]
roxindole Hs Partial agonist 5.8 – 6.0 pKi 40,48
pKi 5.8 – 6.0 [40,48]
SL65.0155 Hs Partial agonist 5.3 pKi 45
pKi 5.3 [45]
CP-122288 Hs Full agonist 7.6 pIC50 11
pIC50 7.6 [11]
L-772,405 Hs Full agonist 6.8 pIC50 61
pIC50 6.8 [61]
8-OH-DPAT Hs Full agonist 6.2 pIC50 11
pIC50 6.2 [11]
View species-specific agonist tables
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
GR-55562 Hs Antagonist 7.4 pKB 19
pKB 7.4 [19]
[3H]N-methyl-AZ10419369 Hs Antagonist 9.4 pKd 33
pKd 9.4 (Kd 3.7x10-10 M) [33]
[3H]GR 125,743 Hs Antagonist 8.6 – 9.2 pKd 14,82
pKd 8.6 – 9.2 (Kd 2.6x10-9 – 7.1x10-10 M) [14,82]
GR-127935 Hs Antagonist 9.2 pKi 14
pKi 9.2 [14]
SB 224289 Hs Inverse agonist 8.2 – 8.6 pKi 13,47,65
pKi 8.2 – 8.6 [13,47,65]
5-OH-DPAT Mm Antagonist 8.4 pKi 36
pKi 8.4 [36]
mianserin Mm Antagonist 8.3 pKi 36
pKi 8.3 [36]
spiperone Mm Antagonist 8.3 pKi 36
pKi 8.3 [36]
ketanserin Mm Antagonist 8.3 pKi 36
pKi 8.3 [36]
yohimbine Mm Antagonist 8.3 pKi 36
pKi 8.3 [36]
SB236057 Hs Inverse agonist 8.2 pKi 38
pKi 8.2 [38]
cyanopindolol Mm Antagonist 8.1 pKi 36
pKi 8.1 [36]
(-)-pindolol Mm Antagonist 8.1 pKi 36
pKi 8.1 [36]
SB 272183 Hs Antagonist 8.1 pKi 78
pKi 8.1 [78]
SB 649915 Hs Antagonist 8.0 pKi 76
pKi 8.0 [76]
methiothepin Hs Inverse agonist 7.1 – 8.5 pKi 14,47,51,79
pKi 7.1 – 8.5 [14,47,51,79]
GR-55562 Hs Antagonist 7.5 pKi 14
pKi 7.5 [14]
metergoline Hs Antagonist 7.2 pKi 51
pKi 7.2 [51]
zotepine Hs Antagonist 7.2 pKi 64
pKi 7.2 [64]
yohimbine Hs Antagonist 6.8 – 7.6 pKi 41,80
pKi 6.8 – 7.6 [41,80]
methysergide Hs Antagonist 6.6 – 7.6 pKi 51,80
pKi 6.6 – 7.6 [51,80]
sertindole Hs Antagonist 7.0 pKi 64
pKi 7.0 [64]
rauwolscine Hs Antagonist 6.5 – 7.4 pKi 51,80
pKi 6.5 – 7.4 [51,80]
risperidone Hs Antagonist 6.6 – 7.0 pKi 28,64
pKi 6.6 – 7.0 [28,64]
9-OH-risperidone Hs Antagonist 6.8 pKi 64
pKi 6.8 [64]
SB 714786 Hs Antagonist 6.7 pKi 76
pKi 6.7 [76]
(S)-flurocarazolol Hs Antagonist 6.5 pKi 59
pKi 6.5 [59]
pipamperone Hs Antagonist 6.2 pKi 64
pKi 6.2 [64]
S33084 Hs Antagonist 6.1 pKi 39
pKi 6.1 [39]
(R)-flurocarazolol Hs Antagonist 6.1 pKi 59
pKi 6.1 [59]
(+)-WAY 100135 Hs Antagonist 5.8 pKi 9
pKi 5.8 [9]
ocaperidone Hs Antagonist 6.9 – 7.2 pIC50 28
pIC50 6.9 – 7.2 [28]
ritanserin Hs Antagonist 6.0 – 6.5 pIC50 11,28
pIC50 6.0 – 6.5 [11,28]
ketanserin Hs Antagonist 5.2 – 5.4 pIC50 11,28
pIC50 5.2 – 5.4 [11,28]
View species-specific antagonist tables
Antagonist Comments
It is possible that radioligand [3H]N-methyl-AZ10419369 may have properties as a partial agonist at the 5-HT1B receptor [33].
Allosteric Regulators
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
5-HT-moduline Hs Negative 11.9 pIC50 60
pIC50 11.9 [60]
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  30,83
Tissue Distribution
Benign and malignant prostate tissue.
Species:  Human
Technique:  Western blotting.
References:  10
Brain: substantia nigra, globus pallidus > striatum > amygdala, hippocampus, septa region, hypothalamus.
Species:  Human
Technique:  Radioligand binding.
References:  72
Trigeminal ganglion.
Species:  Human
Technique:  immunocytochemistry.
References:  18
Cortical cerebral arteries (smooth muscle cell layer > endothelial cell layer).
Species:  Human
Technique:  immunocytochemistry.
References:  49
Coronary artery > atrium > ventricle, epicardium.
Species:  Human
Technique:  RT-PCR.
References:  50
Brain: substantia nigra, globus pallidus > caudate nucleus, putamen, nucleus accumbens, central gray, hippocampal formation > various cortical regions.
Species:  Human
Technique:  Radioligand binding.
References:  5
Brain: striatum, cortex, lateral geniculate nucleus, raphe nucleus.
Species:  Human
Technique:  in situ hybridisation.
References:  73
Suprachiasmatic nucleus.
Species:  Mouse
Technique:  Electron microscopic immunocytochemistry.
References:  4,55
Hypothalamus: magnocellular nuclei > supraoptic nucleus, paraventricular nucleus (dorsolateral) and accessory perifornical, circular and retrochiasmatic nuclei.
Species:  Rat
Technique:  Immunohistochemistry.
References:  34
Lumbar dorsal root ganglia, superior cervical ganglia, lumbar sympathetic ganglia.
Species:  Rat
Technique:  RT-PCR.
References:  56
Suprachiasmatic nucleus.
Species:  Rat
Technique:  Radioligand binding.
References:  35
Trigeminal ganglion.
Species:  Rat
Technique:  Immunohistochemistry.
References:  32
Thymus, peripheral blood lymphocytes, spleen, mitogen-activated spleen cells.
Species:  Rat
Technique:  RT-PCR.
References:  70
CNS: ventral pallidum, globus pallidus, dorsal subiculum, substantia nigra > caudate–putamen, entopeduncular nucleus, superficial gray layer of the superior colliculus, deep nuclei of the cerebellum > cerebral cortex, thalamus.
Species:  Rat
Technique:  immunocytochemistry.
References:  62
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in mouse adrenal Y-1 cells transfected with the 5-HT1B receptor.
Species:  Human
Tissue:  Y-1 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  80
Measurement of cAMP levels in rat C6 glial cells transfected with the human 5-HT1B receptor.
Species:  Human
Tissue:  C6 glial cells.
Response measured:  Inhibition of cAMP accumulation.
References:  53
Measurement of cell growth ([3H]thymidine incorporation) of rat C6 glial cells transfected with the 5-HT1B receptor.
Species:  Human
Tissue:  C6 glial cells.
Response measured:  Cell proliferation.
References:  53
Measurement of cAMP levels in COS-7 cells transfected with the rat 5-HT1B receptor.
Species:  Rat
Tissue:  COS-7 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  1
Measurement of cAMP levels in NIH3T3 cells endogenously expressing the 5-HT1B receptor.
Species:  Mouse
Tissue:  NIH3T3 cell line.
Response measured:  Inhibition of cAMP accumulation.
References:  36
Physiological Functions
Vasoconstriction.
Species:  Human
Tissue:  Coronary artery.
References:  50
Vasocontriction.
Species:  Human
Tissue:  Cortical cerebral artery.
References:  49
Mediation of impulsivity and prefrontal cortex-dependent learning and memory.
Species:  Mouse
Tissue:  In vivo.
References:  52
Regulation of hippocampal functions.
Species:  Rat
Tissue:  In vivo.
References:  7
Inhibition of food intake.
Species:  Rat
Tissue:  In vivo.
References:  27
Presynaptic inhibition of GABA release onto GABAB receptors but not GABAA.
Species:  Rat
Tissue:  Dopamine-containing neurons of the midbrain.
References:  23
Inhibition of GABA release.
Species:  Rat
Tissue:  Globus pallidus.
References:  8
Relief from akinesia.
Species:  Rat
Tissue:  In vivo.
References:  8
Lowering of hippocampal excitatory synaptic transmission.
Species:  Rat
Tissue:  CA1 pyramidal neurons.
References:  42
Inhibition of glutamatergic synaptic transmission.
Species:  Rat
Tissue:  Hypoglossal motoneurons.
References:  68
Presynaptic inhibition of 5-HT (autoreceptor function), GABA and glutamate release (heteroreceptor function).
Species:  Mouse
Tissue:  Dorsal raphe, ventral midbrain and nucleus accumbens.
References:  44
Presynaptic decrease in retinal input to the circadian system.
Species:  Mouse
Tissue:  in vivo (retinal axons in the suprachiasmatic nucleus).
References:  55
Antinociception.
Species:  Mouse
Tissue:  Ventrolateral periaqueductal gray.
References:  3
Regulation of aggressive behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  63
Presynaptic inhibition of 5-HT release.
Species:  Mouse
Tissue:  in vivo (frontal cortex and ventral hippocampus).
References:  71
Presynaptic inhibition of acetylcholine release.
Species:  Rat
Tissue:  Hippocampus.
References:  37
Presynaptic inhibition of dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  2
Physiological Consequences of Altering Gene Expression
5-HT1B receptor knockout mice exhibit altered decision making abilities and response inhibition.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  52
5-HT1B receptor knockout mice exhibit facilitated reference memory and impaired delay-dependent working memory.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  81
Juvenile 5-HT1B receptor knockout mice exhibit reduced anxiety and hyperactivity, reduced sensitivity to 5-HT1A receptor activity and reduced 5-HT1A receptor abundance in some brain regions.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  12
5-HT1B receptor knockout mice lack inhibition of 5-HT, GABA and glutamate release in the CNS.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  44
5-HT1B knockout mice exhibit increased aggressive behaviour.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  63
5-HT1B knockout mice exhibit a reduced effect of cocaine on the induction of the immediate-early gene c-fos, commonly used as a molecular marker for neuronal activation. Indicates that this receptor subtype is involved in mediating the stimulatory effects of cocaine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  31
5-HT1B receptor knockout mice exhibit no inhibition of 5-HT release in the frontal cortex and ventral hippocampus.
Species:  Mouse
Tissue: 
Technique:  Transgenesis.
References:  71
5-HT1B knockout mice exhibit altered monoamine metabolism in the CNS.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  2
5-HT1B receptor knockout mice exhibit elevated extracellular dopamine levels and dopamine release in the nucleus accumbens.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  67
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0000285 abnormal heart valve morphology PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0003313 abnormal locomotor activation PMID: 12798274 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas * 129S6/SvEvTac
MGI:96274  MP:0002803 abnormal operant conditional behavior PMID: 12742250 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0005006 abnormal osteoblast physiology PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0000057 abnormal osteogenesis PMID: 19041748 
Htr1b+|Htr1btm1Rhn Htr1btm1Rhn/Htr1b+
involves: 129S2/SvPas
MGI:96274  MP:0000057 abnormal osteogenesis PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001463 abnormal spatial learning PMID: 12798274 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0003141 cardiac fibrosis PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001364 decreased anxiety-related response PMID: 10996411 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0005140 decreased cardiac muscle contractility PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001489 decreased startle reflex PMID: 11164514 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0002795 dilated cardiomyopathy PMID: 16380550 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
MGI:96274  MGI:96285  MP:0003958 heart valve hyperplasia PMID: 16380550 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001354 increased aggression towards males PMID: 8091214 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001260 increased body weight PMID: 11164514  11790410 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0005605 increased bone mass PMID: 19041748 
Htr1b+|Htr1btm1Rhn Htr1btm1Rhn/Htr1b+
involves: 129S2/SvPas
MGI:96274  MP:0005605 increased bone mass PMID: 19041748 
Htr1b+|Htr1btm1Rhn|Tg(Vil-cre)20Syr|Tph1+|Tph1tm1Kry Htr1btm1Rhn/Htr1b+,Tph1tm1Kry/Tph1+,Tg(Vil-cre)20Syr/0
involves: 129S2/SvPas * C57BL/6 * DBA/2
MGI:3053809  MGI:96274  MGI:98796  MP:0005605 increased bone mass PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0003911 increased drinking behavior PMID: 11790410 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0004988 increased osteoblast cell number PMID: 19041748 
Htr1b+|Htr1btm1Rhn Htr1btm1Rhn/Htr1b+
involves: 129S2/SvPas
MGI:96274  MP:0004988 increased osteoblast cell number PMID: 19041748 
Htr1btm1Rhn Htr1btm1Rhn/Htr1btm1Rhn
involves: 129S2/SvPas
MGI:96274  MP:0001147 small testis PMID: 11790410 
Biologically Significant Variants
Type:  Single nucleotide polymorphism.
Species:  Human
Description:  861 G -> C polymorphism of the HTR1B gene: 861G allele linked to the development of attention deficit hyperactivity disorder (ADHD).
References:  17,58
Type:  Single nucleotide polymorphism.
Species:  Human
Description:  861 G -> C polymorphism: 861G allele linked to antisocial personality and conduct disorder in alcoholics.
References:  69
Type:  Single nucleotide polymorphism.
Species:  Human
Description:  861 G -> C polymorphism: 861C allele linked to the development of alcohol-dependence.
References:  16
Type:  Single nucleotide polymorphism.
Species:  Human
Description:  861 G -> C polymorphism: 861C allele linked with substance abuse disorder and major depression.
References:  20
Available Assays
DiscoveRx PathHunter® eXpress HTR1B U2OS β-Arrestin GPCR Assay (Cat no. 93-0697E3CP6M)
PathHunter® U2OS HTR1B β-Arrestin Cell Line (Cat no. 93-0697C3)
more info

REFERENCES

1. Adham N, Romanienko P, Hartig P, Weinshank RL, Branchek T. (1992) The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptamine1D beta receptor. Mol Pharmacol41: 1-7. [PMID:1732716]

2. Ase AR, Reader TA, Hen R, Riad M, Descarries L. (2000) Altered serotonin and dopamine metabolism in the CNS of serotonin 5-HT(1A) or 5-HT(1B) receptor knockout mice. J Neurochem75: 2415-2426. [PMID:11080193]

3. Bartsch T, Knight YE, Goadsby PJ. (2004) Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol56: 371-381. [PMID:15349864]

4. Belenky MA, Pickard GE. (2001) Subcellular distribution of 5-HT(1B) and 5-HT(7) receptors in the mouse suprachiasmatic nucleus. J Comp Neurol432: 371-388. [PMID:11246214]

5. Bonaventure P, Schotte A, Cras P, Leysen JE. (1997) Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand. Recept. Channels5 (3-4): 225-30. [PMID:9606727]

6. Boulenguez P, Segu L, Chauveau J, Morel A, Lanoir J, Delaage M. (1992) Biochemical and pharmacological characterization of serotonin-O-carboxymethylglycyl[125I]iodotyrosinamide, a new radioiodinated probe for 5-HT1B and 5-HT1D binding sites. J. Neurochem.58 (3): 951-9. [PMID:1738002]

7. Buhot MC, Naili S. (1995) Changes in exploratory activity following stimulation of hippocampal 5-HT1A and 5-HT1B receptors in the rat. Hippocampus5: 198-208. [PMID:7550615]

8. Chadha A, Sur C, Atack J, Duty S. (2000) The 5HT(1B) receptor agonist, CP-93129, inhibits [(3)H]-GABA release from rat globus pallidus slices and reverses akinesia following intrapallidal injection in the reserpine-treated rat. Br J Pharmacol130: 1927-1932. [PMID:10952684]

9. Davidson C, Ho M, Price GW, Jones BJ, Stamford JA. (1997) (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. Br J Pharmacol121: 737-742. [PMID:9208142]

10. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA. (2004) Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate59: 328-336. [PMID:15042609]

11. Domenech T, Beleta J, Palacios JM. (1997) Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol356: 328-334. [PMID:9303569]

12. El-Khodor BF, Dimmler MH, Amara DA, Hofer M, Hen R, Brunner D. (2004) Juvenile 5HT(1B) receptor knockout mice exhibit reduced pharmacological sensitivity to 5HT(1A) receptor activation. Int J Dev Neurosci22: 405-413. [PMID:15380839]

13. Gaster LM, Blaney FE, Davies S, Duckworth DM, Ham P, Jenkins S, Jennings AJ, Joiner GF, King FD, Mulholland KR, Wyman PA, Hagan JJ, Hatcher J, Jones BJ, Middlemiss DN, Price GW, Riley G, Roberts C, Routledge C, Selkirk J, Slade PD. (1998) The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem41: 1218-1235. [PMID:9548813]

14. Granas C, Larhammar D. (1999) Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor. Eur J Pharmacol380: 171-181. [PMID:10513577]

15. Hamblin MW, Metcalf MA, McGuffin RW, Karpells S. (1992) Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. Biochem Biophys Res Commun184: 752-759. [PMID:1315531]

16. Hasegawa Y, Higuchi S, Matsushita S, Miyaoka H. (2002) Association of a polymorphism of the serotonin 1B receptor gene and alcohol dependence with inactive aldehyde dehydrogenase-2. J Neural Transm109: 513-521. [PMID:11956970]

17. Hawi Z, Dring M, Kirley A, Foley D, Kent L, Craddock N, Asherson P, Curran S, Gould A, Richards S, Lawson D, Pay H, Turic D, Langley K, Owen M, O'Donovan M, Thapar A, Fitzgerald M, Gill M. (2002) Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. Mol Psychiatry7: 718-725. [PMID:12192616]

18. Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L. (2001) 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res909: 112-120. [PMID:11478927]

19. Hoyer D, Hannon JP, Martin GR. (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav.71 (4): 533-54. [PMID:11888546]

20. Huang YY, Oquendo MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM, Khait V, Mann JJ. (2003) Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology28: 163-169. [PMID:12496953]

21. Jin H, Oksenberg D, Ashkenazi A, Peroutka SJ, Duncan AM, Rozmahel R, Yang Y, Mengod G, Palacios JM, O'Dowd BF. (1992) Characterization of the human 5-hydroxytryptamine1B receptor. J Biol Chem267: 5735-5738. [PMID:1348246]

22. John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, Valentin JP, Palmier C, Wurch T, Chopin P, Marien M, Kleven MS, Koek W, Assie MB, Carilla-Durand E, Tarayre JP, Colpaert FC. (1999) F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. J Pharmacol Exp Ther290: 83-95. [PMID:10381763]

23. Johnson SW, Mercuri NB, North RA. (1992) 5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. J Neurosci12: 2000-2006. [PMID:1578282]

24. Jorand-Lebrun C, Pauwels PJ, Palmier C, Moret C, Chopin P, Perez M, Marien M, Halazy S. (1997) 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem40: 3974-3978. [PMID:9397179]

25. Koe BK, Nielsen JA, Macor JE, Heym J. (1992) Biochemical and behavioural studies of the 5-HT1B receptor agonist, CP-94,253. Drug Development Research26: 241-250.

26. Law H, Dukat M, Teitler M, Lee DK, Mazzocco L, Kamboj R, Rampersad V, Prisinzano T, Glennon RA. (1998) Benzylimidazolines as h5-HT1B/1D serotonin receptor ligands: a structure-affinity investigation. J Med Chem41: 2243-2251. [PMID:9632357]

27. Lee MD, Kennett GA, Dourish CT, Clifton PG. (2002) 5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253. Psychopharmacology (Berl)164: 49-60. [PMID:12373419]

28. Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE. (1998) Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol123: 1655-1665. [PMID:9605573]

29. Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Haegeman G, Schotte A, Van Gompel P, Wouters R, Lesage AS. (1996) Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol50: 1567-1580. [PMID:8967979]

30. Lin SL, Setya S, Johnson-Farley NN, Cowen DS. (2002) Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family. Br J Pharmacol136: 1072-1078. [PMID:12145108]

31. Lucas JJ, Segu L, Hen R. (1997) 5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol51: 755-763. [PMID:9145913]

32. Ma QP. (2001) Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport12: 1589-1591. [PMID:11409721]

33. Maier DL, Sobotka-Briner C, Ding M, Powell ME, Jiang Q, Hill G, Heys JR, Elmore CS, Pierson ME, Mrzljak L. (2009) [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy. J. Pharmacol. Exp. Ther.330 (1): 342-51. [PMID:19401496]

34. Makarenko IG, Meguid MM, Ugrumov MV. (2000) Distribution of serotonin 5-hydroxytriptamine 1B (5-HT(1B)) receptors in the normal rat hypothalamus. Neurosci Lett.328: 155-159. [PMID:12133578]

35. Manrique C, Hery F, Faudon M, Francois-Bellan AM. (1999) Indirect evidence for an association of 5-HT(1B) binding sites with retinal and geniculate axon terminals in the rat suprachiasmatic nucleus. Synapse33: 314-323. [PMID:10421712]

36. Maroteaux L, Saudou F, Amlaiky N, Boschert U, Plassat JL, Hen R. (1992) Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A89: 3020-3024. [PMID:1557407]

37. Maura G, Raiteri M. (1986) Cholinergic terminals in rat hippocampus possess 5-HT1B receptors mediating inhibition of acetylcholine release. Eur J Pharmacol129: 333-337. [PMID:3780847]

38. Middlemiss DN, Göthert M, Schlicker E, Scott CM, Selkirk JV, Watson J, Gaster LM, Wyman P, Riley G, Price GW. (1999) SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur. J. Pharmacol.375 (1-3): 359-65. [PMID:10443589]

39. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther293: 1048-1062. [PMID:10869410]

40. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther303: 791-804. [PMID:12388666]

41. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP, Cogé F, Galizzi JP, Boutin JA, Rivet JM, Dekeyne A, Gobert A. (2000) Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse35: 79-95. [PMID:10611634]

42. Mlinar B, Corradetti R. (2003) Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons. Eur J Neurosci18: 1559-1571. [PMID:14511335]

43. Mochizuki D, Yuyama Y, Tsujita R, Komaki H, Sagai H. (1992) Cloning and expression of the human 5-HT1B-type receptor gene. Biochem Biophys Res Commun185: 517-523. [PMID:1610347]

44. Morikawa H, Manzoni OJ, Crabbe JC, Williams JT. (2000) Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. Mol Pharmacol58: 1271-1278. [PMID:11093763]

45. Moser PC, Bergis OE, Jegham S, Lochead A, Duconseille E, Terranova JP, Caille D, Berque-Bestel I, Lezoualc'h F, Fischmeister R, Dumuis A, Bockaert J, George P, Soubrie P, Scatton B. (2002) SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther302: 731-741. [PMID:12130738]

46. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol368: 259-268. [PMID:10193663]

47. Newman-Tancredi A, Audinot V, Moreira C, Verriele L, Millan MJ. (2000) Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT(1B) receptor/G-protein stoichiometry. Mol Pharmacol58: 1042-1049. [PMID:11040052]

48. Newman-Tancredi A, Cussac D, Audinot V, Millan MJ. (1999) Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol359: 447-453. [PMID:10431754]

49. Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L. (1999) Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol128: 1133-1140. [PMID:10578124]

50. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T, Edvinsson L. (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol372: 49-56. [PMID:10374714]

51. Parker EM, Izzarelli DG, Lewis-Higgins L, Palmer D, Shapiro RA. (1996) Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem67: 2096-2103. [PMID:8863519]

52. Pattij T, Broersen LM, van der Linde J, Groenink L, van der Gugten J, Maes RA, Olivier B. (2003) Operant learning and differential-reinforcement-of-low-rate 36-s responding in 5-HT1A and 5-HT1B receptor knockout mice. Behav Brain Res141: 137-145. [PMID:12742250]

53. Pauwels PJ, Wurch T, Amoureux MC, Palmier C, Colpaert FC. (1996) Stimulation of cloned human serotonin 5-HT1D beta receptor sites in stably transfected C6 glial cells promotes cell growth. J Neurochem66: 65-73. [PMID:8522991]

54. Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, Nelson DL, Calligaro DO, Kiefer AD, Branchek TA, Flaugh ME. (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci61: 2117-212. [PMID:9395253]

55. Pickard GE, Smith BN, Belenky M, Rea MA, Dudek FE, Sollars PJ. (1999) 5-HT1B receptor-mediated presynaptic inhibition of retinal input to the suprachiasmatic nucleus. J Neurosci19: 4034-4045. [PMID:10234032]

56. Pierce PA, Xie GX, Levine JD, Peroutka SJ. (1996) 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience70: 553-559. [PMID:8848158]

57. Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Gothert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN. (1997) SB-216641 and BRL-15572 compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch. Pharmacol.356: 312-320. [PMID:9303567]

58. Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, Basile VS, Beitchman J, Kennedy JL. (2003) The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. Mol Psychiatry8: 98-102. [PMID:12556913]

59. Roth BL, Ernsberger P, Steinberg SA, Rao S, Rauser L, Savage J, Hufeisen S, Berridge MS, Muzic RF. (2001) The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl)157: 111-114. [PMID:11512051]

60. Rousselle JC, Plantefol M, Fillion MP, Massot O, Pauwels PJ, Fillion G. (1998) Specific interaction of 5-HT-moduline with human 5-HT1b as well as 5-HT1d receptors expressed in transfected cultured cells. Naunyn Schmiedebergs Arch Pharmacol358: 279-286. [PMID:9774213]

61. Russell MG, Matassa VG, Pengilley RR, van Niel MB, Sohal B, Watt AP, Hitzel L, Beer MS, Stanton JA, Broughton HB, Castro JL. (1999) 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem42: 4981-5001. [PMID:10585208]

62. Sari Y, Miquel MC, Brisorgueil MJ, Ruiz G, Doucet E, Hamon M, Verge D. (1999) Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience88: 899-915. [PMID:10363826]

63. Saudou F, Amara DA, Dierich A, LeMeur M, Ramboz S, Segu L, Buhot MC, Hen R. (1994) Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science265: 1875-1878. [PMID:8091214]

64. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl)124: 57-73. [PMID:8935801]

65. Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN, Price GW. (1998) SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol125: 202-208. [PMID:9776361]

66. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology28: 1400-1411. [PMID:12784105]

67. Shippenberg TS, Hen R, He M. (2000) Region-specific enhancement of basal extracellular and cocaine-evoked dopamine levels following constitutive deletion of the Serotonin(1B) receptor. J Neurochem75: 258-265. [PMID:10854269]

68. Singer JH, Bellingham MC, Berger AJ. (1996) Presynaptic inhibition of glutamatergic synaptic transmission to rat motoneurons by serotonin. J Neurophysiol76: 799-807. [PMID:8871200]

69. Soyka M, Preuss UW, Koller G, Zill P, Bondy B. (2004) Association of 5-HT1B receptor gene and antisocial behavior in alcoholism. J Neural Transm111: 101-109. [PMID:14714219]

70. Stefulj J, Jernej B, Cicin-Sain L, Rinner I, Schauenstein K. (2000) mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun14: 219-224. [PMID:10970681]

71. Trillat AC, Malagie I, Scearce K, Pons D, Anmella MC, Jacquot C, Hen R, Gardier AM. (1997) Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies. J Neurochem69: 2019-2025. [PMID:9349547]

72. Varnas K, Hall H, Bonaventure P, Sedvall G. (2001) Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743. Brain Res.915: 47-57. [PMID:11578619]

73. Varnas K, Hurd YL, Hall H. (2005) Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse56: 21-28. [PMID:15700286]

74. Voigt MM, Laurie DJ, Seeburg PH, Bach A. (1991) Molecular cloning and characterization of a rat brain cDNA encoding a 5-hydroxytryptamine1B receptor. Embo J10: 4017-4023. [PMID:1836757]

75. Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V, Han GW, Liu W, Huang XP, Vardy E et al.. (2013) Structural Basis for Molecular Recognition at Serotonin Receptors. Science,  [Epub ahead of print]. [PMID:23519210]

76. Ward SE, Harrington FP, Gordon LJ, Hopley SC, Scott CM, Watson JM. (2005) Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem48: 3478-3480. [PMID:15887956]

77. Watson J, Brough S, Coldwell MC, Gager T, Ho M, Hunter AJ, Jerman J, Middlemiss DN, Riley GJ, Brown AM. (1998) Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol125: 1413-1420. [PMID:9884068]

78. Watson J, Roberts C, Scott C, Kendall I, Collin L, Day NC, Harries MH, Soffin E, Davies CH, Randall AD, Heightman T, Gaster L, Wyman P, Parker C, Price GW, Middlemiss DN. (2001) SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol133: 797-806. [PMID:11454652]

79. Watson JM, Burton MJ, Price GW, Jones BJ, Middlemiss DN. (1996) GR127935 acts as a partial agonist at recombinant human 5-HT1D alpha and 5-HT1D beta receptors. Eur J Pharmacol314: 365-372. [PMID:8957260]

80. Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR. (1992) Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1Dα and 5-HT1Dβ. Proc. Natl. Acad. Sci. U.S.A.89: 3630-3634. [PMID:1565658]

81. Wolff M, Benhassine N, Costet P, Hen R, Segu L, Buhot MC. (2003) Delay-dependent working memory impairment in young-adult and aged 5-HT1BKO mice as assessed in a radial-arm water maze. Learn Mem10: 401-409. [PMID:14557613]

82. Xie Z, Lee SP, O'Dowd BF, George SR. (1999) Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett.456 (1): 63-7. [PMID:10452531]

83. Zgombick JM, Branchek TA. (1998) Native 5-HT1B receptors expressed in OK cells display dual coupling to elevation of intracellular calcium concentrations and inhibition of adenylate cyclase. Naunyn Schmiedebergs Arch Pharmacol358: 503-508. [PMID:9840417]

To cite this database page, please use the following:

Rodrigo Andrade, Nicholas M. Barnes, Gordon Baxter, Joel Bockaert, Theresa Branchek, Marlene L. Cohen, Aline Dumuis, Richard M. Eglen, Manfred Göthert, Mark Hamblin, Michel Hamon, Paul R. Hartig, René Hen, Katharine Herrick-Davis, Rebecca Hills, Daniel Hoyer, Patrick P. A. Humphrey, Klaus Peter Latté, Luc Maroteaux, Graeme R. Martin, Derek N. Middlemiss, Ewan Mylecharane, Stephen J. Peroutka, Pramod R. Saxena, Andrew Sleight, Carlos M. Villalon, Frank Yocca.
5-Hydroxytryptamine receptors: 5-HT1B receptor. Last modified on 10/02/2014. Accessed on 25/04/2014. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=2.

Contact us | Print | Back to top | Help
Copyright © 2014 IUPHAR